Corbus 15min chart triggers Bollinger Bands Narrowing, Bearish Marubozu formation observed.
ByAinvest
Monday, Sep 29, 2025 1:32 pm ET1min read
CRBP--
The trading session was marked by a general decline in the stock market, with the NASDAQ Composite Index (COMP) falling 0.50% to 22,384.70 and the Dow Jones Industrial Average (DJIA) dropping 0.38% to 45,947.32. Despite this, Corbus Pharmaceuticals Holdings Inc. managed to outperform some of its competitors, including Vanda Pharmaceuticals Inc. (VNDA), Fortress Biotech Inc. (FBIO), and Viking Therapeutics Inc. (VKTX). Vanda Pharmaceuticals Inc. fell 1.43% to $4.83, Fortress Biotech Inc. rose 1.63% to $3.75, and Viking Therapeutics Inc. dropped 5.78% to $25.09 [1].
Trading volume for Corbus Pharmaceuticals Holdings Inc. was robust, with 134,222 shares traded, exceeding its 50-day average volume of 123,286 [1]. This strong trading volume indicates investor interest in the stock.
On September 29, 2025, at 13:30, Corbus's 15-minute chart exhibited Bollinger Bands Narrowing and a Bearish Marubozu pattern. These technical indicators suggest a decrease in stock price volatility, control by sellers, and a probable continuation of bearish momentum.
Investors should closely monitor Corbus Pharmaceuticals Holdings Inc.'s performance and technical indicators to make informed decisions. The company's stock price has shown resilience despite broader market declines, and its recent performance indicates potential for further analysis.
On September 29, 2025, at 13:30, Corbus's 15-minute chart exhibited Bollinger Bands Narrowing and a Bearish Marubozu pattern, indicating a decrease in stock price volatility, control by sellers, and a probable continuation of bearish momentum.
On Thursday, September 29, 2025, shares of Corbus Pharmaceuticals Holdings Inc. (CRBP) advanced 5.38% to $12.14, marking a significant performance improvement during a broader market downturn. The stock's rise snapped a two-day losing streak, closing 47.96% short of its 52-week high of $23.33, achieved on September 26, 2025 [1].The trading session was marked by a general decline in the stock market, with the NASDAQ Composite Index (COMP) falling 0.50% to 22,384.70 and the Dow Jones Industrial Average (DJIA) dropping 0.38% to 45,947.32. Despite this, Corbus Pharmaceuticals Holdings Inc. managed to outperform some of its competitors, including Vanda Pharmaceuticals Inc. (VNDA), Fortress Biotech Inc. (FBIO), and Viking Therapeutics Inc. (VKTX). Vanda Pharmaceuticals Inc. fell 1.43% to $4.83, Fortress Biotech Inc. rose 1.63% to $3.75, and Viking Therapeutics Inc. dropped 5.78% to $25.09 [1].
Trading volume for Corbus Pharmaceuticals Holdings Inc. was robust, with 134,222 shares traded, exceeding its 50-day average volume of 123,286 [1]. This strong trading volume indicates investor interest in the stock.
On September 29, 2025, at 13:30, Corbus's 15-minute chart exhibited Bollinger Bands Narrowing and a Bearish Marubozu pattern. These technical indicators suggest a decrease in stock price volatility, control by sellers, and a probable continuation of bearish momentum.
Investors should closely monitor Corbus Pharmaceuticals Holdings Inc.'s performance and technical indicators to make informed decisions. The company's stock price has shown resilience despite broader market declines, and its recent performance indicates potential for further analysis.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet